Unraveling the mechanism of action of thiazolidinediones
Open Access
- 1 December 2000
- journal article
- editorial
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 106 (11) , 1305-1307
- https://doi.org/10.1172/jci11705
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinedionesJournal of Clinical Investigation, 2000
- Insights into insulin resistance and type 2 diabetes from knockout mouse modelsJournal of Clinical Investigation, 2000
- Loss of Insulin Signaling in Hepatocytes Leads to Severe Insulin Resistance and Progressive Hepatic DysfunctionPublished by Elsevier ,2000
- Surgical implantation of adipose tissue reverses diabetes in lipoatrophic miceJournal of Clinical Investigation, 2000
- Tissue-Specific Knockout of the Insulin Receptor in Pancreatic β Cells Creates an Insulin Secretory Defect Similar to that in Type 2 DiabetesCell, 1999
- Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.Journal of Clinical Investigation, 1998
- Troglitazone action is independent of adipose tissue.Journal of Clinical Investigation, 1997
- 15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγCell, 1995
- mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.Genes & Development, 1994
- Targeted expression of a toxin gene to adipose tissue: transgenic mice resistant to obesity.Genes & Development, 1993